Sarah Cannon Research Institute Oncology Research Consortium

Sarah Cannon Research Institute (SCRI) is a global leader in oncology clinical research, specializing in the development of innovative cancer therapies. As a premier clinical research organization (CRO) and site management organization, SCRI provides a comprehensive network of strategic research sites across the United States and United Kingdom. The institute offers end-to-end clinical trial capabilities, including drug development services, molecular profiling, and trial management from Phase 1 through Phase 3. SCRI has played a pivotal role in the clinical development of over 600 first-in-human trials and has contributed to the majority of FDA-approved cancer therapies since its inception. By integrating research directly into community-based cancer care, SCRI significantly expands patient access to cutting-edge treatments and accelerates the search for a cure.